Corporate Presentation
September 2023
Disclaimer
Some of the statements contained in this presentation constitute forward-looking statements. Statements that are not historical facts are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may",
"will", "expect", "intend", "estimate", "anticipate", "believe", "continue" or similar terminology. These
statements are based on the Company's current strategy, plans, objectives, assumptions, estimates and projections. Investors should therefore not place undue reliance on those statements. The Company makes no representation, warranty or prediction that the results anticipated by such forward-looking statements will be achieved, and such forward-looking statements represent, in each case, only one of many possible scenarios and should not be viewed as the most likely or standard scenario. Forward-looking statements speak only as of the date that they are made and the Company does not undertake to update any forward-looking statements in light of new information or future events. Forward-looking statements involve inherent risks and uncertainties. The Company cautions that a number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.
2
Poxel's Mission & Key Investment Highlights
To discover, develop and commercialize innovative therapies for patients suffering from serious chronic and rare diseases with underlying metabolic pathophysiology
acetyl CoA
METABOLIC INFLAMMATION
DISORDERS
(cellular energy
homeostasisTISSUE
imbalances) DEGENERATION & CELL DEATH
apoptosis,
necrosis
Strategic focus on rare metabolic diseases and NASH
Royalties from TWYMEEG® (Imeglimin), approved and launched in Japan in 2021 for Type 2 Diabetes
Proven capabilities to build solid partnerships and to lead drug development
Highly Experienced Management Team in
Metabolic Diseases
3
Key Financial & Shareholder Information
Market data | Shareholder ownership1 | |
Bpi France
12,2%
Ticker: POXEL
ISIN: FR0012432516
Number of shares: 35,258,1121
Key financials
-
As of 6/30/23 cash & cash equivalents:
EUR 7.6 million
Founders
8,3%
Floating
79,5%
Analyst coverage
Bryan Garnier | Alex Cogut |
Degroof Petercam | David Seynnaeve |
JMP Securities | Jason Butler |
4 | 1. As of August 31, 2023. For the most up to date share count, please refer to the website: Regulatory Documentation | Poxel SA (poxelpharma.com) |
Leadership Team
Highly Experienced Management Team; Extensive R&D and Metabolic Expertise
Pascale Fouqueray (MD, PhD) | |
Thomas Kuhn (Pharm D, | EVP, Clinical Development & |
MBA) | Regulatory Affairs, |
Chief Executive Officer and | Co-founder |
Co-founder |
Sébastien Bolze (Pharm D,
PhD)
EVP, Chief Operating Officer
(COO), Co-founder
Sylvie Bertrand | |
Sophie Bozec (PhD) | Vice President, Human |
SVP, R&D Pharmacology & | Resources |
Scientific Communication, | |
Co-founder | |
Quentin Durand | |
EVP, Chief Legal Officer and | |
Head of CSR Corporate | |
Social Responsibility |
5
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Poxel SA published this content on 05 September 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 September 2023 09:27:06 UTC.